News

Osborne Clarke advises Terumo on the acquisition of Quirem Medical


Written on 16 July 2020

Osborne Clarke in Amsterdam has advised Terumo, a global leader in medical technology based in Tokyo, Japan on the acquisition of Quirem Medical, a Netherlands-based healthcare start-up specializing in the development of next-generation microspheres for Selective Internal Radiation Therapy (SIRT), a treatment for liver tumors.

Under the terms of the agreement, Terumo acquired 80.1% of the shares of Quirem Medical. This is over and above its current share position of 19.9%, making Quirem Medical now a wholly owned subsidiary of Terumo. Terumo will make a one-time, up-front payment with additional payments based on the achievement of future milestones by 2030.

Quirem Medical’s Holmium products are currently available in Europe, the Middle East and Africa (EMEA). In the coming years, Terumo intends to launch the Holmium Platform globally as part of the ongoing expansion of its interventional oncology (IO) portfolio.

The Osborne Clarke team was led by Partner Herke van Hulst and included Senior Associate Marie-Louise Weeda, Associate Guusje Cornelissen, Civil-law Notary Cars-Jan van Gool and prospective  Civil-Law Notary Mechteld Flohil, Tax Partner Job van der Pol, Employment Partner Jorgo Tsiris, Senior Associate Coen Barneveld Binkhuysen (commercial/IP) and Associates Marleen Huisman (IP/data protection), Wyke Schilstra (employment) and Aram Hovanesjan (tax).

Osborne Clarke’s international life science and healthcare sector team has a strong track record of providing highly sophisticated advice to investors and medical device and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market. Recent notable work from the team in Amsterdam includes advising the syndicate of investors in the EUR 32 million Series B financing round of VarmX. and advising iOnctura on the EUR 20.1 Series A financing round and the sale of Breath Therapeutics to Zambon.

Connect with one of our experts


Herke van Hulst

Partner, Advocaat, The Netherlands

T +31 20 702 8672

Email Herke

Full Biog

Marie-Louise Weeda

Senior Associate, Advocaat, The Netherlands

T +31 20 702 8698

Email Marie-Louise

Full Biog

Guusje Cornelissen

Associate, Advocaat, The Netherlands

T +31 20 702 8642

Email Guusje

Full Biog

Cars-Jan van Gool

Partner, Civil Law Notary (notaris), The Netherlands

T +31 20 702 8664

Email Cars-Jan

Full Biog

Job van der Pol

Partner, Head of Tax, The Netherlands

T +31 20 70 28920

Email Job

Full Biog

Mechteld Flohil

Associate Director, The Netherlands

T +31 20 70 28912

Email Mechteld

Full Biog

Jorgo Tsiris

Partner, Advocaat, The Netherlands

T +31 20 702 8618

Email Jorgo

Full Biog

Coen Barneveld Binkhuysen

Senior Associate, Advocaat, The Netherlands

T +31 20 702 8612

Email Coen

Full Biog

Marleen Huisman

Associate, Advocaat, The Netherlands

T +31 20 702 8674

Email Marleen

Full Biog

Wyke Schilstra

Associate, Advocaat, The Netherlands

T +31 20 702 8676

Email Wyke

Full Biog

Aram Hovanesjan

Associate, Lawyer, The Netherlands

T +31 20 70 28610

Email Aram

Full Biog